South Korea grants first approval worldwide to a stem cell therapy
This article was originally published in Clinica
South Korea's FDA has granted the first commercial clearance in a regulated market to a therapy based on adult stem cells, awarding a marketing approval to FCB-Pharmicell's acute myocardial infarction (AMI) product Hearticellgram-AMI.
You may also be interested in...
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Japanese firm exercises option after promising Phase I results in disorder with no approved drugs, in deal that builds out its celiac pipeline.